Table 1.
Baseline clinical characteristics of patients treated with radium-223.
| Characteristic | Patients (38) |
|---|---|
| Age | |
| Median (range), yr | 74.02 (56–86) |
| <75 yr, no. (%) | 18 (47.3) |
| ≥75 yr, no. (%) | 20 (52.6) |
| ECOG performance status score, no. (%) | |
| 0 | 4 (10.5) |
| 1 | 18 (47.3) |
| ≥2 | 16 (42.2) |
| Extent of disease, no. (%) | |
| <6 metastases | 9 (23.6) |
| 6–20 metastases | 7 (25) |
| >20 metastases | 22 (57.8) |
| Median basal biochemical values (range) | |
| Hemoglobin, g/dL | 12.6 (10.3–15.2) |
| Total alkaline phosphatase, U/liter | 125.1 (58–255) |
| PSA, ng/dL | 46.9 (0.17–419) |
| Pain at baseline, n (%) | |
| Mild | 8 (21.1) |
| Moderate | 24 (63.1) |
| Severe | 6 (15.8) |
| Any previous use of docetaxel, no. (%) | |
| Yes | 24 (63.2) |
| Also Abi/Enza no. (% of yes) | 11 (45.8) |
| Also cabazitaxel no. (% of yes) | 12 (50) |
| No | 14 (36.8) |
| Only ADT (% of not) | 8 (57.2) |
| ADT + Abi/Enza (% of not) | 6 (42.8) |
| Previous external-beam radiation therapy, no. (%) | |
| Yes | 8 (21.05) |
| Prostate | 4 (10.5) |
| Bone | 6 (15.7) |
| Current use of bisphosphonates, no. (%) | |
| Yes | 8 (21.05) |
| Current use of denosumab, no. (%) | |
| Yes | 3 (7.8) |
PSA, prostate-specific antigen.